However, we believe this difference did not affect our result due to no significant differences of PAR2 expression between hepatitis B and C. Finally, further studies in health individuals, and patients with other liver diseases, such as alcoholic liver disease and metabolic associated fatty liver disease, should be done to validate the role of PAR2 in the general population. This evidence concerns the gene F2RL1 and alcoholic liver diseases.